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The proliferation of vascular smooth muscle cells (VSMCs) plays a major role in the pathogenesis of many cardiovascular 
diseases. Geminin regulates DNA replication and cell cycle progression and plays a key role in the proliferation of cancer cells. 
We therefore hypothesized that geminin regulates the proliferation of VSMCs. The present study demonstrates that the level of 
geminin expression was low in quiescent VSMCs (approximately 90% and 10% of cells in the G1 and in S/G2/M phases of the 
cell cycle, respectively), increased as more cells entered in S/G2/M, and then decreased as cells exited S/G2/M. Further, angi-
otensin II and norepinephrine stimulated expression of geminin in VSMCs. However, the DNA content, nuclear morphology, 
percentage of cells at different stages of the cell cycle, and rate of proliferation of VSMCs from which geminin was either de-
pleted or overexpressed were all similar. These findings indicate geminin functions differently in VSMCs than it does in cancer 
cell lines and that it may provide a target for treating cancers without affecting normal cells. 
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The proliferation of vascular smooth muscle cell (VSMCs) 
is adaptive and essential for vasculogenesis and vascular 
repair after injury. However, excessive proliferation con-
tributes to the pathogenesis of many cardiovascular diseases, 
including atherosclerosis, restenosis after angioplasty, and 
hypertension [1,2]. Although a large number of molecules, 
including inflammatory cytokines and growth factors, can 
promote the proliferation of VSMCs, therapeutic strategies 
targeting cell cycle may provide the best approach for in-
hibiting proliferation [3], because all proliferating cells must 
transit the cell cycle. 
A critical function of the cell cycle is to ensure that the 
chromosomal DNA is replicated faithfully and completely 
and is followed by mitosis once in each cell cycle. When 
DNA replication initiates in eukaryotes, the origin recogni-
tion complex binds to initiator elements and recruits the cell 
division cycle 6 and chromatin licensing and DNA replica-
tion factor 1 (Cdt1) to chromatin in the G1 phase of the cell 
cycle. This is followed by the loading of a replicative hel-
icase (minichromosome maintenance complex components, 
MCM) onto chromatin that binds to cell division cycle 6 
and Cdt1 to form the pre-replication complex (pre-RC), 
which unwinds chromosomes at replication forks and initi-
ates DNA synthesis. After DNA replication origin firing at 
the beginning of S phase, the pre-RC dissociates from 
chromatin and is not reassembled until the cell passes 
through mitosis into the G1 phase of the next cycle [4–6].  
Geminin, a cell cycle regulator, prevents DNA rereplica-
tion by preventing the loading of the MCM complex on 
chromatin to safeguard genomic stability [7]. Geminin is 
degraded during G1, accumulates during S, G2, and M, and 
is degraded at the metaphase-anaphase transition [8]. Sub-
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sequently, a study found that geminin blocks the binding of 
the MCM complex to replication origins primarily by bind-
ing with high affinity to Cdt1 during S and G2 [6]. Deple-
tion of geminin by using RNA interference induces DNA 
rereplication as manifested by the appearance of giant nu-
clei and increased DNA content (greater than 4N). DNA 
rereplication induced by depletion of geminin activates the 
Chk1 and Chk2 G2/M checkpoints, which prevents cells 
with over-replicated DNA from entering mitosis and sub-
sequently inhibits cell proliferation [7,9,10].  
Overexpression of geminin in a human breast non-tumor- 
igenic cell line and in breast cancer cell line stimulates pro-
gression through G-S as well as cell proliferation [11]. Fur-
ther, geminin is expressed at low levels in organs with 
minimal proliferative activity capacity (heart, nerves, pros-
tate, kidney, lung, and skeletal muscle) and at high levels in 
proliferating lymphocytes, male germ cells, and epithelial 
cells [1214]. This suggests that geminin acts as a regulator 
of cell proliferation. We therefore hypothesize that geminin 
regulates the proliferation of VSMCs by regulating DNA 
replication and cell cycle progression. 
1  Materials and methods 
1.1  Construction of geminin protein and shRNA ex-
pression vectors 
To isolate a geminin cDNA from rat cells, forward 
(5-CGGAATTCATGAATCTCAGTATGAAGCAGAAA-  
CAGG-3) and reverse (5-CGGGATCCCCTGTACACG- 
CCGTGCCATC-3) primers were designed (accession No. 
NM_001106112.1). A standard reverse transcriptase poly-
merase chain reaction (PCR) was performed using RNA 
isolated from the rat A10 aortic smooth muscle cells line 
(CRL 1476, American Type Culture Collection, Manassas, 
VA, USA) as template. The purified products were ligated 
to a mammalian vector that expresses enhanced green fluo-
rescent protein pEGFP-N1 to generate a recombinant vector 
designated pEGFP-N1-Geminin. Three siRNAs targeting 
geminin and a negative control siRNA were synthesized at 
Shanghai GenePharma Co., Ltd. (Shanghai, China). The 
double-stranded siRNA sequences are as follows: Gemi-
nin-rat-738: 5-GCCUGAGAAAGGAGAAUAATT-3, 5- 
UUAUUCUCCUUUCUCAGGCTT-3; Geminin-rat-417: 
5-GGAGAACGCUGAAGAUGAUTT-3, 5-AUCAUCU- 
UCAGCGUUCUCCTT-3; Geminin-rat-658: 5-GAGGA- 
AAGCUCUCUAUGAATT-3, 5-UUCAUAGAGAGCUU- 
UCCUCTT-3. 
We cotransfected 293T cells with pEGFP-N1-Geminin 
together with each siRNA and Lipofectamine 2000 (Invi-
trogen, USA) and selected the most inhibitory siRNA ac-
cording to observations using a fluorescence microscope. A 
single-stranded hairpin siRNA (shRNA) vector based on the 
most effective siRNA was constructed at the SinoGenoMax 
Co., Ltd. (Beijing, China). An adenovirus expressing this 
shRNA and the gene encoding geminin were also con-
structed at the SinoGenoMax Co., Ltd.  
1.2  Cell culture 
The A-10 rat aortic smooth muscle cells line and HeLa cells 
(CCL-2, American Type Culture Collection, Manassas, VA, 
USA) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, Life Technologies, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS), 100 U mL1 
penicillin and 100 µg mL1 streptomycin. Synchronous 
populations of quiescent VSMCs were obtained by incubat-
ing cells with DMEM containing 0.5% FBS for 24 h. Cells 
were then treated with DMEM containing 10% FBS and 
harvested at 0, 9, 12, 15, 18, 24 h following serum restimu-
lation to determine geminin expression. Synchronized 
VSMCs cultured in DMEM containing 0.5% FBS were also 
treated with angiotensin II (Ang-II), norepinephrine (NE) 
and were harvested at 24 h. Ang-II and NE were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). 
VSMCs were infected with adenoviral vectors (Ad-null, 
Ad-geminin Ad-non-silence, Ad-shRNA) at a multiplicity 
of infection of 200. The medium was then changed to 
DMEM containing 10% FBS and the cells were harvested at 
0, 24 and 48 h for the analyses as described in the following 
sections. 
1.3  Western blot analysis 
Western blot analysis of whole cell lysates was performed 
as previously described [15]. Briefly, the cells were lysed in 
RIPA buffer (P0013C, Beyotime Institute of Biotechnology, 
China). The cell lysates were centrifuged at 13000×g at 4°C 
for 20 min and the supernatant was collected. The total pro-
tein concentrations were measured with a BCA protein as-
say kit (Pierce, USA) according to the manufacturer’s in-
structions. Electrophoresis of equal amounts of total protein 
was on a 10% SDS-PAGE gel. Transfer was done in wet 
conditions. The primary antibodies were incubated over-
night at 4°C. Horseradish peroxidase (HRP)-conjugated 
secondary antibody was incubated for 2 h. Antibodies pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA) are as follows (dilutions, catalog numbers): 
geminin (1:500) (sc-74496), GAPDH (1:500) (sc-137179) 
and HRP-conjugated secondary antibody (1:3000) (sc- 
2005). The GAPDH antibody served as internal control.   
1.4  Flow cytometry and cell proliferation assays 
Cells were collected by trypsinization, and washed with 
phosphate-buffered saline (PBS), fixed with 70% ethanol 
overnight at 4°C. After fixation, cells were collected by 
centrifugation and incubated with RNaseA at 37°C for   
30 min, then stained with propidium iodide at 4°C for    
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30 min. The labeled cell suspension was filtered and ana-
lyzed on Becton Dickinson FACSCalibur. 
Cell proliferation was assayed using a Cell Counting 
Kit-8 (CCK-8, Dojindo Kumamoto Prefecture, Japan) ac-
cording to the manufacturer’s instructions. Briefly, cells 
were seeded in 96-well plates. At the indicated times, 10 µL 
of the CCK-8 solution was added into each well and then 
incubated for 2 h at 37°C. The absorbance was measured by 
GENios Pro reader (Tecan, Switzerland) at the wavelength 
of 450 nm. 
1.5  Nuclear staining 
Cells were fixed in 4% paraformaldehyde for 10 min and 
permeabilized with 0.2% Triton X-100 for 20 min. Cells 
were incubated with solution containing DAPI for 5 min 
and then to visualize their nuclei by a laser scanning confo-
cal microscope (Leica, Germany). 
1.6  Statistical analyses 
The data are expressed as mean±standard deviation (SD). 
Comparisons were analyzed by using Student’s t-test or 
ANOVA. Differences were considered statistically signifi-
cant at P<0.05. Analyses were performed using SPSS v.16.0 
software. 
2  Results 
2.1  Expression of geminin in VSMCs 
Because geminin is undetectable during G1 phase, and ac-
cumulates during the S, G2, and M phases in HeLa cell and 
MCF-7 [8,16], we determined whether the pattern of the 
geminin expression was similar in rat VSMCs. As shown in 
Figure 1, the level of geminin expression was low in quies-
cent VSMCs (approximately 90% in G1), increased with the 
increase in cells transiting S/G2/M after serum restimulation, 
and then decreased as cells exited from S/G2/M.  
We next determined the expression levels of geminin in 
cells treated with angiotensin II and NE, which are major 
contributors to cardiovascular disease. As shown in Figure 2, 
angiotensin II (102 µmol L1) and NE (1 µmol L1) signifi-
cantly stimulated the proliferation of VSMCs and the ex-
pression of geminin. 
2.2  Efficiency of methods for silencing and over-   
expressing geminin in VSMCs 
To determine the role of geminin in the proliferation of 
VSMCs, we infected cells with adenoviruses expressing a 
cDNA encoding geminin and a geminin-specific shRNA. 
To establish the optimum conditions for inhibiting geminin 
expression, we cotransfected 293T cells with the pEGFP- 
N1-geminin expression vector and one of three distinct 
geminin-specific siRNAs. Geminin expression was inhibited 
most effectively by the siRNA designated 738 (Figure 3A). 
We next constructed an adenovirus vector expressing a 
geminin-specific shRNA using this siRNA sequence. Figure 
3B shows that the expression of geminin in VSMCs infected 
with adenovirus vectors Ad-geminin and Ad-shRNA was 
significantly increased and decreased compared with con-




Figure 1  Analysis of geminin expression during the VSMC cell cycle. A, Western blot analysis of geminin expression in cells during G1 and S+G2/M. 
Cells were synchronized as described in Materials and methods and sampled at the indicated times. GAPDH served as a loading control. Geminin expression 
levels are normalized to the 0 h value. B, Analysis of the VSMC cell cycle.  
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Figure 2  Analysis of geminin expression in cells treated with Ang-II and NE. Synchronous populations of quiescent VSMCs were treated with Ang-II and 
NE as described in Materials and methods. A, Cell cycle analysis. B, CCK-8 cell proliferation assay. *, P<0.01 (Ang-II or NE vs. control). C, Western blot 
analysis of geminin expression in untreated and Ang-II and NE treated cells. HeLa cells served as a positive control. The figure shows one of three 
independent experiments. 
 
Figure 3  Evaluation of methods for silencing or overexpressing geminin in VSMCs. A, Effect of different geminin siRNAs on geminin expression. GFP 
fluorescence was detected as described in Materials and methods. B, Western blot analysis of geminin overexpression and inhibition by RNA silencing. 
VSMCs were infected with adenoviral expression vectors (Ad-null, Ad-geminin, Ad-non-silence, and Ad-shRNA) as described in Materials and methods. 
pEGFP-N1-geminin vector for expressing an EGFP-geminin fusion protein. NC, negative control. 
2.3  Effects of geminin on the proliferation of VSMCs 
The ability to inhibit or induce geminin expression in 
VSMCs using RNAi or transgene expression, respectively, 
facilitated our efforts to determine the effects of geminin on 
DNA replication, cell cycle progression, and proliferation. 
We found that either inhibition of geminin expression or 
overexpression did not significantly affect the DNA content 
or nuclear morphology of VSMCs compared with controls. 
Moreover, the percentage of cells at different phases of the 
cell cycle and the proliferative ability of VSMCs were also 
similar to the control values (Figures 46, Table 1). Be-
cause the expression levels of geminin fluctuate during the  
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Figure 4  Analysis of DNA content using flow cytometry. VSMCs were infected with adenoviral vectors (Ad-null, Ad-geminin, Ad-non-silence, and 
Ad-shRNA) and stained with propidium iodide as described in Materials and methods. A minimum of 10000 events were analyzed.  
cell cycle [8] and the peak is at 15 h in the present study, we 
also determined DNA content, nuclear morphology and 
proliferation at 15 h after inhibiting geminin expression and 
did not detect significant differences compared with the 
controls, the results were also similarly compared with con-
trol (Figures S1–S3, Table S1 in Supporting Information). 
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Figure 5  Nuclear morphology of VSMCs infected with Ad-null, Ad-geminin, Ad-non-silence, and Ad-shRNA at 0, 24, and 48 h following restimulation 
with serum. Cells were stained with 4′,6-diamidino-2-phenylindole to visualize nuclei using a laser scanning confocal microscope. The figure shows one of 
three independent experiments. 
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Table 1  Distribution of VSMCs in different stages of the cell cycle in Ad-null, Ad-geminin, Ad-non-silence, Ad-shRNA groups at 0, 24 and 48 h after 
serum restimulation 
Groups  G1 (%) S (%) G2/M (%) 
Ad-null 
0 h 
86.48±1.64 5.70±1.01 7.82±0.68 
Ad-geminin 87.41±2.80 6.17±1.15 6.43±1.72 
Ad-non-silence 87.51±1.52 5.90±0.63 6.59±2.08 
Ad-shRNA 86.73±2.12 5.78±1.04 7.51±1.10 
Ad-null 
24 h 
65.14±1.54 24.21±1.34 10.64±0.69 
Ad-geminin 64.98±2.6 23.99±1.39 11.04±1.24 
Ad-non-silence 65.02±2.08 23.28±3.2 11.69±2.04 
Ad-shRNA 65.25±2.29 24.19±2.61 10.62±0.83 
Ad-null 
48 h 
78.67±2.19 12.73±1.01 8.59±1.22 
Ad-geminin 78.98±2.21 12.61±0.96 8.40±1.34 
Ad-non-silence 79.26±2.45 11.95±2.52 8.79±0.43 
Ad-shRNA 77.84±1.38 12.69±0.66 9.46±1.63 
 
 
Figure 6  Effect of geminin on VSMC proliferation. Cells were infected 
with adenoviral vectors (Ad-null, Ad-geminin, Ad-non-silence, and 
Ad-shRNA) as described in Materials and methods. The absorbance of 
cells was measured at 450 nm at 0, 24, 48, and 72 h after restimulation with 
serum. 
3  Discussion 
By interacting with Cdt1, geminin acts to prevent the reli-
censing of replication origins after they have fired once and 
accumulating evidence indicates that geminin plays an im-
portant role in maintaining the integrity of the genome. Pro-
liferating normal cells, such as lymphocytes, male germ 
cells and epithelial cells, and cancer cell lines, express high 
levels of geminins. Depletion of geminin leads to additional 
rounds of replication in some cancer cells while overex-
pression of geminin stimulates progression through G1-S. In 
the present study, we show that VSMCs expressed geminin 
at low levels in G1 phase and accumulated it during S, G2, 
and M phases. Angiotensin II and NE, which are important 
factors in the pathogenesis of vascular proliferative diseases, 
also stimulated the VSMCs to express high levels of gemi-
nin, which supports its role in these diseases. However, in-
hibiting or overexpressing geminin in VSMCs did not sig-
nificantly alter DNA content, nuclear morphology, the dis-
tribution of cells in the G1, S, G2/M phases or proliferative 
capacity compared with controls. Therefore, we conclude 
that geminin is dispensable for the regulation of VSMC 
proliferation.  
We note that studies showing that DNA rereplication is 
induced by depleting geminin from eukaryotic cells were 
performed using the HCT116 human colorectal cancer cell 
line, the H1299 human lung cancer cell line, the US2OS 
human osteosarcoma cell line as well as others [7,9,10]. In 
contrast, the findings of our present studies using VSMCs 
are not consistent with the results of these studies. Therefore, 
the role of geminin in the regulation of the cell cycle ma-
chinery may be different in normal tissues or nontumor-
igenic cell lines from that in cancer cell lines. Although we 
did not further determine why the geminin was dispensable 
for regulation of DNA replication in VSMCs, we hypothe-
size the mechanism of that as follows. Cdt1 activity is the 
rate-limiting step in pre-RC assembly, and that geminin is 
the critical regulator of Cdt1 activity. Cdt1 activity is also 
regulated by other mechanisms in addition to geminin: (i) 
Cdt1 is phosphorylated by cyclin A-dependent kinases (cy-
clin A/Cdk1 and cyclin A/Cdk2), causing Cdt1 to bind the 
F-box protein Skp2, a component of the Skp1-Cullin1-F- 
box protein ubiquitin ligase complex, Skp2 then degrades 
Cdt1. (ii) Cdt1 is regulated by Cul4-based ubiquitin ligase- 
and PCNA-mediated proteolysis during S phase [17]. In 
normal cells, these mechanisms contribute to restricting 
genome duplication to once per cell division. Our findings 
that inhibiting geminin expression in VSMCs did not induce 
DNA rereplication in contrast to certain cancer cell lines  
suggest that the two pathways described above are inactive 
in cancer cell lines, but are active in VSMCs and compen-
sate for the loss of geminin function. 
Enforced overexpression of geminin stimulates cell pro-
liferation and mediates an increase in the percentage of cells 
in S phase and is associated with a reduction in the per-
centage of the cells in G0/G1 phase [11]. In contrast, in the 
present study, the percentage of VSMCs at different stages 
of the cell cycle was not significantly altered compared with 
controls whether geminin was depleted or overexpressed.  
Geminin is expressed at high levels in cancer cell lines of 
different histological origins as well as in primary colon, 
rectal, and breast tumors [11]. Primary breast cancers over-
express geminin at an early stage of progression suggesting 
that geminin plays an important role in initiating tumor-
igenesis [11]. Moreover, increased geminin expression is a 
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powerful independent indicator of adverse prognosis in in-
vasive breast cancer [16] and analysis of geminin expression 
may be useful for predicting the prognosis of patients with 
colorectal cancer [18]. These findings provide compelling 
evidence that geminin initiates and sustains malignant 
transformation, which is in stark contrast to our present re-
sults demonstrating that geminin was dispensable for the 
proliferation of VSMCs. Therefore, the difference between 
the role of geminin in the proliferation of cancer and normal 
cells suggests that it can be targeted to tumors without ad-
verse effects on normal tissues.  
In conclusion, geminin is expressed during the S, G2, 
and M phases of the cell cycle in VSMCs but is dispensable 
for their proliferation in contrast to cell lines derived from 
human cancers. This apparent phenotype-specific difference 
in geminin function between normal and cancer cells im-
plies that specific targeting of geminin in tumor cells may 
be a potential therapeutic strategy for treating cancers.  
This work was supported by Beijing Municipal Natural Science Founda-
tion (5102040). 
1 Kawai-Kowase K, Owens G K. Multiple repressor pathways contri- 
bute to phenotypic switching of vascular smooth muscle cells. Am J 
Physiol Cell Physiol, 2007, 292: C59–69 
2 Owens G K, Kumar M S, Wamhoff B R. Molecular regulation of 
vascular smooth muscle cell differentiation in development and 
disease. Physiol Rev, 2004, 84: 767–801 
3 Charron T, Nili N, Strauss B H. The cell cycle: a critical therapeutic 
target to prevent vascular proliferative disease. Can J Cardiol, 2006, 
22(Suppl B): 41B–55B 
4 Stillman B. Cell cycle control of DNA replication. Science, 1996, 
274: 1659–1664 
5 Dutta A, Bell S P. Initiation of DNA replication in eukaryotic cells. 
Ann Rev Cell Dev Biol, 1997, 13: 293–332 
6 Wohlschlegel J A, Dwyer B T, Dhar S K, et al. Inhibition of 
eukaryotic DNA replication by geminin binding to cdt1. Science, 
2000, 290: 2309–2312 
7 Mihaylov I S, Kondo T, Jones L, et al. Control of DNA replication 
and chromosome ploidy by geminin and cyclin A. Mol Cell Biol, 
2002, 22: 1868–1880 
8 McGarry T J, Kirschner M W. Geminin, an inhibitor of DNA 
replication, is degraded during mitosis. Cell, 1998, 93: 1043–1053 
9 Zhu W, Chen Y, Dutta A. Rereplication by depletion of geminin is 
seen regardless of p53 status and activates a G2/M checkpoint. Mol 
Cell Biol, 2004, 24: 7140–7150 
10 Melixetian M, Ballabeni A, Masiero L, et al. Loss of geminin induces 
rereplication in the presence of functional p53. J Cell Biol, 2004, 165: 
473–482 
11 Montanari M, Boninsegna A, Faraglia B, et al. Increased expression 
of geminin stimulates the growth of mammary epithelial cells and is a 
frequent event in human tumors. J Cell Physiol, 2005, 202: 215–222 
12 Wohlschlegel J A, Kutok J L, Weng A P, et al. Expression of 
geminin as a marker of cell proliferation in normal tissues and 
malignancies. Am J Pathol, 2002, 161: 267–273 
13 Eward K L, Obermann E C, Shreeram S, et al. DNA replication 
licensing in somatic and germ cells. J Cell Sci, 2004, 117: 5875–5886 
14 Montanari M, Macaluso M, Cittadini A, et al. Role of geminin: from 
normal control of DNA replication to cancer formation and 
progression? Cell Death Diff, 2006, 13: 1052–1056 
15 Pang X, Sun N L. Calcineurin-NFAT signaling is involved in 
phenylephrine-induced vascular smooth muscle cell proliferation. 
Acta Pharmacol Sin, 2009, 30: 537–544 
16 Gonzalez M A, Tachibana K E, Chin S F, et al. Geminin predicts 
adverse clinical outcome in breast cancer by reflecting cell-cycle 
progression. J Pathol, 2004, 204: 121–130 
17 Fujita M. Cdt1 revisited: complex and tight regulation during the cell 
cycle and consequences of deregulation in mammalian cells. Cell Div, 
2006, 1: 22 
18 Nishihara K, Shomori K, Tamura T, et al. Immunohistochemical 
expression of geminin in colorectal cancer: implication of prognostic 
significance. Oncol Rep, 2009, 21: 1189–1195 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
 
Supporting Information 
Table S1  Effect of geminin in VSMCs proliferation 
Figure S1 Western blot analysis for efficiency of geminin knocking down.VSMCs were infected with adenoviral vectors (Ad-non-silence, Ad-shRNA) in 
DMEM containing 0.5% FBS for 24 h. The medium was then changed to DMEM containing 10% FBS and the cells were harvested at 0 and 15 h following 
serum restimulation. 
Figure S2 DNA content was analyzed by flow cytometric analysis and cells distribution in different phases of the cell cycle. VSMCs were infected with 
adenoviral vectors (Ad-non-silence, Ad-shRNA) in DMEM containing 0.5% FBS for 24 h. The medium was then changed to DMEM containing 10% FBS 
and harvested at 0 and 15 h following serum re-stimulation. The cells were trypsinized and washed, and DNA was stained with propidium iodide. Cell cycle 
analysis was performed with a minimum of 10000 events per analysis by using flow cytometric analysis. 
Figure S3 The nuclei morphology of VSMCs infected with Ad-non-silence, Ad-shRNA at 0 and 15 h following serum restimulation. Cells were stained with 
DAPI to visualize their nuclei by laser scanning confocal microscope. 
The supporting information is available online at life.scichina.com and www.springerlink.com. The supporting materials 
are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains en-
tirely with the authors. 
